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ORIGINAL RESEARCH
Association Between Patient- Clinician 
Relationships and Adherence to 
Antihypertensive Medications Among Black 
Adults: An Observational Study Design
Teng- Jen Chang, MS, PhD; John F. P. Bridges, PhD; Mary Bynum , DHA, MA, RN; John W. Jackson , 
MPH, ScD; Joshua J. Joseph, MD; Michael A. Fischer, MD, MS; Bo Lu, PhD; Macarius M. Donneyong ,  
MPH, PhD
BACKGROUND: We assessed the associations between patient- clinician relationships (communication and involvement in 
shared decision- making [SDM]) and adherence to antihypertensive medications.
METHODS AND RESULTS: The 2010 to 2017 Medical Expenditure Panel Survey (MEPS) data were analyzed. A retrospective 
cohort study design was used to create a cohort of prevalent and new users of antihypertensive medications. We defined 
constructs of patient- clinician communication and involvement in SDM from patient responses to the standard question-
naires about satisfaction and access to care during the first year of surveys. Verified self- reported medication refill information 
collected during the second year of surveys was used to calculate medication refill adherence; adherence was defined as 
medication refill adherence ≥80%. Survey- weighted multivariable- adjusted logistic regression models were used to measure 
the odds ratio (OR) and 95% CI for the association between both patient- clinician constructs and adherence. Our analysis 
involved 2571 Black adult patients with hypertension (mean age of 58 years; SD, 14 years) who were either persistent (n=1788) 
or new users (n=783) of antihypertensive medications. Forty- five percent (n=1145) and 43% (n=1016) of the sample reported 
having high levels of communication and involvement in SDM, respectively. High, versus low, patient- clinician communication 
(OR, 1.38; 95% CI, 1.14– 1.67) and involvement in SDM (OR, 1.32; 95% CI, 1.08– 1.61) were both associated with adherence 
to antihypertensives after adjusting for multiple covariates. These associations persisted among a subgroup of new users of 
antihypertensive medications.
CONCLUSIONS: Patient- clinician communication and involvement in SDM are important predictors of optimal adherence to an-
tihypertensive medication and should be targeted for improving adherence among Black adults with hypertension.
Key Words: adherence ■ antihypertensive medication ■ black adults ■ communication ■ hypertension ■ patient- clinician relationships 
■ shared decision- making
Only 27% to 53% of Black adults are fully adherent to their antihypertensive medications,1– 6 which is associated with increased hypertension morbidity, 
mortality, and avoidable healthcare costs.7– 10 Black pa-
tients experience worse hypertension outcomes, poten-
tially because of poorer adherence to antihypertensive 
medications, compared with all racial groups in the 
United States.3,11– 15 Interventions to increase adherence 
can improve clinical outcomes,16– 18 but only a few have 
been well studied among Black patients.19– 21
Medication adherence functions as a shared agree-
ment between patients and clinicians.22 Patients are 
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more receptive to clinical recommendations when 
there is an engaged partnership.23,24 Existing con-
ceptual frameworks have often placed adherence to 
medications as an intermediary outcome between 
patient- clinician relationships and health outcomes.25,26 
Communication and shared decision- making (SDM) 
have shown direct and indirect effects on medica-
tion adherence.25,26 The indirect pathways between 
these tenets of the patient- clinician relationships and 
medication adherence are mediated by proximal 
affective- cognitive outcomes (eg, trust in clinicians, 
satisfaction with health care, and understanding) of the 
patient- clinician relationship.26
Patients are more likely to be adherent to medi-
cations, in general, when they have good commu-
nication with their clinician.27 A few studies among 
small samples of Black patients (n=92– 723) found 
a positive relationship between patient- clinician 
communication and adherence to antihypertensive 
medications.28– 31 Three separate systematic reviews 
reported that there is insufficient data to determine 
the effect of SDM on medication adherence in the 
general population and among socioeconomically 
disadvantaged groups.26,32,33
Methodological limitations regarding the use of cross- 
sectional study designs, small sample sizes of Black pa-
tients (n=92– 723), lack of geographically representative 
populations, and self- reported measures of adherence 
limit the scientific rigor of the extant evidence base for 
the association between patient- clinician relationships 
and adherence. Disentangling these relationships with 
cross- sectional and cohort studies, where exposures 
and outcomes are measured at single fixed time points, 
is difficult. For instance, patients with controlled blood 
pressure (BP) tend to be more adherent, yet adher-
ence to antihypertensive medications is also shown to 
improve BP control.34– 36 Patients with poor health out-
comes, such as uncontrolled BP, also tend to have neg-
ative perceptions of interactions with clinicians.37,38
We therefore sought to leverage a nationally repre-
sentative healthcare utilization data set to assess the 
associations between patient- clinician relationships 
(communication and involvement in SDM) and adher-
ence to antihypertensive medications among Black 
adults with hypertension. A better understanding of 
the associations between patients’ perspectives about 
their communication and SDM with clinicians on ad-
herence could help guide the formulation of effective 
interventions to improve antihypertensive medication 
adherence among Black patients.
METHODS
We will make our analytic methods available to other 
researchers upon request. Medical Expenditure 
Panel Survey (MEPS) is publically available. The data 
that support the findings of this study are available 
from the MEPS website: https://www.meps.ahrq.gov/
mepsw eb/. The use of this publically available data 
set did not require institutional review board approval.
Data Source and Setting
We analyzed data from Household Component of the 
Medical Expenditure Panel Survey (MEPS- HC) from 
CLINICAL PERSPECTIVE
What Is New?
• The effects of patient- provider relationships on 
adherence to antihypertensive medication ther-
apy were observed among Black adults but not 
among other racial/ethnic groups.
• Our data elucidated the associations between 
patient- provider relationships (communication 
and shared decision- making) and adherence to 
antihypertensive medications using a large na-
tional longitudinal data set.
What Are the Clinical Implications?
• Black patients may be more likely to benefit from 
effective communication and higher involve-
ment in shared decision- making with respect 
to antihypertensive medication adherence than 
are other ethnic groups.
• It is possible that providers who communicate 
effectively and involve Black patients in shared 
decision- making may be less likely to be biased 
against Black patients.
• Black patients are likely to be more trusting of 
providers who communicate effectively and 
involve them in shared decision- making and, 
consequently, are more likely to adhere to treat-
ment recommendation.
Nonstandard Abbreviations and Acronyms
CAHPS consumer assessment of healthcare 
providers and systems
HCAHPS hospital consumer assessment of 
healthcare providers and systems
MEPS medical expenditure panel survey
MEPS- HC household component of the 
medical expenditure panel survey
MRA medication refill adherence
SAQ self- administered questionnaire
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2010 to 2017.39 MEPS- HC data are collected from a na-
tionally representative sample of households through 
an overlapping panel design (Figure 1). These data are 
collected in 5 rounds of interviews during a 2- year pe-
riod. Survey questionnaires are used to gather data on 
self- reported health status, medical conditions, health 
insurance status, healthcare access, prescription 
medication use, and access to and satisfaction with 
the clinician. To verify and obtain detailed prescrip-
tion medication use, respondents are asked to provide 
names of prescription medications obtained and to 
identify the pharmacy where medications were filled. 
MEPS seeks the consent of respondents to contact 
pharmacies to collect the following information about 
drugs obtained: payments, payers, date each prescrip-
tion was filled, quantity dispensed, and the National 
Drug Code.40 The pharmacies also provide information 
on the number of times medications are filled within a 
given calendar year.40
Study Design
Figure 1 is an illustration of how the MEPS panel design 
data were leveraged to create a cohort of antihyper-
tensive medication users. In this illustration, 2 years of 
data from 5 rounds of surveys are combined to create 
a cohort of participants who filled at least 1 prescrip-
tion of antihypertensive medication. Data collected 
from rounds 1 through 3 in 2015 (year 1) were used 
to define patient- clinician constructs (communication 
and SDM) and all potential confounders. The 2016 
data (year 2) were used to define adherence measures 
based on medication refills and the days’ supply of 
filled antihypertensive medications. Among the primary 
analysis cohort, we identified a subgroup of new users 
as patients who only began using antihypertensive 
medications in year 2 but had no prior records of anti-
hypertensive medication use in year 1. The year 1 and 
2 periods are referred to as the baseline and follow- up 
periods, respectively.
Participant Selection
Figure 2 is a flowchart of participant selection. Our analy-
sis included participants who reported a hypertension 
diagnosis and antihypertensive medication use. For the 
patient- clinician communication and adherence analy-
sis, we further restricted the primary analysis to only 
participants who reported visiting a clinic or a doctor’s 
office in the past 12 months; the Consumer Assessment 
of Healthcare Providers and Systems (CAHPS) survey 
questionnaire was administered to only participants who 
met this criterion. Additionally, participants were required 
to have had a usual source of care in the previous year 
to be included in the analysis for measuring the asso-
ciations between SDM and adherence. This restriction 
was necessary because SDM is defined from both the 
CAHPS and access to healthcare survey questionnaires.
Figure 1. Study design.
In this illustration, 2 years of data from 5 rounds of surveys are combined to create a cohort of participants who filled at least 1 
prescription of antihypertensive medication. Data collected from rounds 1 through 3 in 2015 are used to define patient- provider 
engagement factors (shared decision- making, communication, and trust) and all covariates (individual characteristics and provider 
characteristics). On the other hand, the 2016 data are used to define medication refill adherence based on medication refill and the 
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Measurement of Patient- Clinician 
Constructs
Our analysis is based solely on patients’ perspec-
tives about their engagement with clinicians. MEPS 
participants’ perspectives about access to care and 
the quality of health care they received were assessed 
with computer- assisted personal interview and self- 
administered supplemental paper questionnaires 
(Self- Administered Questionnaire [SAQ]), respectively 
(https://www.meps.ahrq.gov/mepsw eb/survey_comp/
survey.jsp#Quest ionna ires). The healthcare qual-
ity measures in SAQ were adapted from the health 
plan version of CAHPS (Consumer Assessment of 
Healthcare Providers and Systems). CAHPS is a relia-
ble and valid tool for capturing information about health 
plans’ performances from racially/ethnically diverse 
consumers.41– 44 CAHPS’ survey items have also been 
used to accurately measure patient- clinician commu-
nication and SDM among all racial/ethnic groups.44,45 
Previous studies have examined the associations 
between medication adherence and patient- clinician 
constructs defined from CAHPS survey items.46– 48 We 
referred to human providers as clinicians in this study.
The patient- clinician communication construct was 
created from participant responses (never, sometimes, 
usually, always) to the questions: how often does the 
care provider (1) listen carefully to the patient; (2) ex-
plain to the patient; (3) show respect to the patient; and 
(4) spend enough time with the patient? The Hospital 
CAHPS (HCAHPS) “top- box” scoring approach was 
used to dichotomize responses to each item as 1 for 
“always” and 0 for any other response.49 These binary 
scores were then summed to generate a composite 
score of patient- clinician communication ranging from 
0 to 4 (“always” to all 4 items).29 Composite scores 
of 4 (“always”) were considered high and those 
<4 were considered low levels of patient- clinician 
communication.49,50
The SDM construct was defined from the 4 CAHPS 
items described above plus 3 additional questions 
about patients’ satisfaction with their usual source of 
care provider: does the usual source of care provider 
(1) usually ask about and show respect for medical, 
traditional, and alternative treatments that the person is 
happy with (never/sometimes/usually/always)?; (2) ask 
the person to help make decisions between a choice of 
treatments (never/sometimes/usually/always)?; and (3) 
usually ask about prescription medications and treat-
ments other doctors may give them (yes/no)?.51 The 
top- box approach was used to dichotomize responses 
into 1 (always) and 0 (never, sometimes, usually) scores 
for the questions with Likert scale responses. “Yes” re-
sponses were coded as 1, whereas “no” responses 
were coded as 0. The sum of these scores ranged 
from 0 to 7, with SDM scores ≥6 considered as high 
and scores <6 considered as low based on the top- 
box approach.49,50
Outcomes
We considered medication refill adherence (MRA) as 
a measure of adherence to antihypertensive medica-
tions. The MEPS Prescribed Medicines Files provide 
Figure 2. Participant selection.
Black adults were identified from the 2010 to 2017 MEPS (Medical Expenditure Panel Survey) data. The 
year 1 data were used for identifying Black patients with a hypertension diagnosis and antihypertensive 
medication (AHM) use. Persistent use, discontinuation, and new use of AHMs were assessed from the 
year 2 data. *Sample for measuring associations between patient- clinician communication and adherence 
to AHMs. †Sample for measuring associations between patient involvement in shared decision- making 
and adherence to AHM. AHM users (n=217) were excluded if they lacked access to a usual source of care 
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detailed information on the type, dosage, and payment 
for each filled prescription for MEPS participants in 
each year. For each individual selected for our analy-
sis, MRA was calculated as the percent of total days’ 
supply of antihypertensives divided by number of days 
of study participation (365  days).52,53 MRA has been 
previously used to measure adherence from the MEPS 
data set.47,54 An overall MRA was obtained as the av-
erage of MRAs calculated for separate therapeutic 
classes of antihypertensive medications if a participant 
was using >1 antihypertensive agent from multiple 
therapeutic classes. Patients were considered to be 
adherent to antihypertensive medications if their overall 
MRA was ≥80%.55– 57
Potential Confounders
The World Health Organization suggests multidimen-
sional frameworks of adherence through which several 
predictors affect medication adherence at the individ-
ual patient, healthcare provider and healthcare system 
levels.58 We applied a directed acyclic graph to identify 
and illustrate the interrelationships between predictors 
of medication adherence as potential confounders of 
the associations between patient- clinician relation-
ships and adherence to antihypertensive medications 
(Figure  3). Through this directed acyclic graph, we 
identified social/economic, patient- related, condition- 
related, and antihypertensive therapy– related factors 
as an individual patient- level potential confounder; a 
detailed list of these variables is provided in Table 1. 
These individual- level factors can influence both 
the patient- clinician relationships and adherence to 
antihypertensive medications directly or indirectly via 
provider characteristics (provider specialty, race, and 
sex) and healthcare system factors (health insurance 
status, source of payment of healthcare services, out- 
of- packet payment, and number of office visits).
Statistical Analysis
Descriptive analysis was conducted to compare the 
frequency and mean distributions of baseline covari-
ates between participants grouped into high versus 
low levels of communication and SDM. Standardized 
difference tests were used to assess the balance of 
baseline covariates between the comparison groups. 
Next, we used logistic regression models weighted by 
MEPS survey weights59 to measure the odds ratios 
(ORs) and 95% CIs for the associations between each 
construct of the patient- clinician relationships and ad-
herence to antihypertensive medications. Because 
the literature shows a worsening trend of hyperten-
sion awareness and control in recent years, we fixed 
a linear time trend in calculating all adjusted ORs.60 
We calculated all estimates (prevalences, averages, 
and ORs) and their standard errors based on stand-
ardized approaches for obtaining weighted estimates 
among subpopulations in MEPS.59 The goal of our 
primary analyses was to measure the following as-
sociations between each patient- clinician construct 
and adherence, modeled as a binary outcome (MRA 
≥80% versus <80%). Communication and SDM were 
modeled both as binary and ordinal- scale independent 
variables.
Three sets of sensitivity analysis were performed to:
Figure 3. Directed acyclic graph (DAG).
This DAG was used for identifying potential confounders of the associations between patient- clinician 
relationships and adherence to antihypertensive medications. The direct paths from each set of 
confounders (patient characteristics, provider characteristics, and healthcare system factors) to the 
primary exposure (patient- clinician relationships) and outcome (adherence) were modeled. Solid lines 
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1. Test for the potential presence of reverse associa-
tions. The potential presence of reverse association 
between adherence and patient- clinician relationships 
is illustrated in the directed acyclic graph (Figure  1) 
by a feedback loop from high BP to adherence and 
back to patient- clinician relationships. For example, 
patients who have their BP under control are most 
likely to adhere and to rate their communication 
and involvement in SDM as high than when their 
high BP is not under control with antihypertensive 
treatment and vice versa. To test for the presence of 
a reverse association, we first repeated the analysis 
among new users of antihypertensive medications. We 
assumed that the reported baseline communication 
and SDM scores are not influenced by patients’ 
adherence behaviors in year 1 since new users did 
not report using antihypertensives in year 1. Therefore, 
any observed associations between patient- clinician 
relationships and adherence among new users are not 
influenced by prior adherence behaviors (assumption 
1). Second, we explored whether prior adherence 
(MRA in year 1) was associated with the patients’ 
perceptions of their communication and involvement 
in SDM; a lack of association would suggest that 
the reported patient- clinician scores are not influenced 
by prior adherence (assumption 2). If both assump-
tions 1 and 2 hold true, then it is unlikely that the 
observed associations in the primary analysis are 
under the influence of potential reverse associations 
between patient- clinician relationships and adherence.
2. Identify individual items of patient- clinician constructs 
associated with adherence. We modeled individual 
items of both communication and SDM constructs 
as the main predictors of adherence by repeating the 
models described in the primary analysis.
3. Assess whether the associations between patient- 
clinician relationships and adherence is modified 
by race/ethnicity. We tested for interaction between 
race/ethnicity (Black versus non- Black individuals) 
and generated race/ethnicity- specific data on the 
associations between patient- clinician relationships 
and adherence.
Between 8% and 12% were missing a response to 
questions about patient- clinician communication and 
SDM; therefore, we imputed values via random selection 
methods.61,62 The distributions of single items and overall 
communication and SDM scores did not change after 
random selection imputation (Table S1 and S2).
RESULTS
Participants
The primary analysis results reported are based on 
a total of 2571 (weighted n=2 039 511) Black adult 
patients with hypertension who had office/clinic visits 
in the past 12 months; 70% (weighted n=1 399 259) 
of these patients were persistent users and 30% 
(weighted n=640 252) started using antihypertensive 
medications during the second year of the MEPS 
surveys. Forty- five percent of the sample had high 
levels of communication with their clinicians. Among 
the 2354 patients (weighted n=1 865 852) who had 
a usual source of care provider and had an office/
clinic visit in the past 12 months, 43% reported hav-
ing high levels of involvement in SDM. The distribu-
tion of responses to individual items are reported in 
Table S2.
Distribution of Participant Characteristics
Table 1 describes the distribution of baseline charac-
teristics by binary levels of patient- clinician commu-
nication (unweighted n=2571; weighted n=2 039 511) 
and patient involvement in the SDM process (un-
weighted n=2354; weighted n=1  865  852) among 
those who responded to CAHPS and the access to 
care questionnaire, respectively. The standardized dif-
ference tests (>0.10) showed that the majority of the 
baseline covariates were balanced between levels of 
communication except for geographic region of resi-
dence (West), healthcare cost– related barriers, health-
care system factors (uninsured, lack of usual source of 
payment), provider specialty (general medical doctor), 
and chronic comorbidities (poor physical and mental 
health, angina, arthritis). Similarly, geographic region 
of residence (Midwest, South, West), healthcare cost– 
related barriers, healthcare system factors (uninsured, 
lack of usual source of payment), provider specialty 
(general medical doctor, nonhuman), and chronic co-
morbidities (poor physical and mental health, angina, 
arthritis). The distribution of responses to patient- 
clinician interactions and baseline characteristics were 
similar before and after missing data imputation (Table 
S3).
Patterns of Prevalence of Adherence by 
Levels of Patient- Clinician Communication 
and Involvement in SDM
The overall prevalence of adherence to antihyperten-
sive medications (MRA ≥80%) was 40% with a median 
MRA of 66% (interquartile range [IQR], 41%– 98%). The 
median MRAs were significantly higher among pa-
tients with high (74.0; IQR, 41.1– 98.6) compared with 
those with low (61.6; IQR, 32.9– 95.9) levels of patient- 
clinician communication (P<0.01). Similarly, patients 
with higher levels of involvement in SDM had higher 
median MRAs (74.0; IQR, 41.1– 98.6) compared with 
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Associations between Patient- Clinician 
Relationships and Adherence to 
Antihypertensive Medications
The associations between patient- clinician relation-
ships and adherence to antihypertensive medications 
among Black adults and other racial/ethnic groups 
are reported in Tables 2 and 3. In multivariable logis-
tic regression analysis, the odds of adherence to an-
tihypertensive medications was 38% (OR, 1.38; 95% 
CI, 1.14– 1.67) higher among Black patients who re-
ported having high levels of communication with their 
clinicians, versus low levels of communication, after 
adjusting for social and economic, patient- related, 
condition- related, and healthcare system/health-
care team factors (Table 2). Black patients were also 
more likely to adhere to antihypertensive medications 
if they felt more involved with the decision- making 
process of their health care than if they did not (OR, 
1.32; 95% CI, 1.08– 1.61) (Table 3). Both ordinal- level 
communication and SDM scores were significantly 
associated with adherence to antihypertensive medi-
cation (Table S4). The odds of adherence increased 
by 14% and 8% for every unit increase in communi-
cation (OR, 1.14; 95% CI, 1.07– 1.22) and SDM scores 
(OR, 1.08; 95% CI, 1.04– 1.15), respectively (Table S4). 
These associations persisted among subgroups of 
new users of antihypertensive medications (Table 
S4).
Sensitivity Analysis
There were 783 (weighted n=640  252) and 692 
(weighted n=571  084) new users of antihypertensive 
medications among participants with communication 
and SDM scores, respectively. Similar to the primary 
analysis, both high levels of communication (OR, 1.45; 
95% CI, 1.01– 2.07) (Table 2) and involvement in SDM 
(OR, 1.59; 95% CI, 1.09– 2.32) (Table  3) were signifi-
cantly associated with adherence to antihypertensive 
medications among new users, consistent with preva-
lent users. Prior adherence (measured in the baseline 
period) was neither associated with patients’ percep-
tions of their communication (OR, 1.09; 95% CI, 0.87– 
1.35) nor their involvement in SDM process (OR, 1.03; 
95% CI, 0.82– 1.29). In the second set of sensitivity 
analysis, all 4 individual items that make up the com-
munication construct were significantly associated 
with adherence to antihypertensive medications (Table 
S5). On the other hand, the additional 3 individual items 
that were combined with the 4 communication items 
were observed to not be significantly associated with 
adherence (Table S5). Black race/ethnicity significantly 
modified the associations between both constructs 
Table 2. Associations Between Patient- Provider Communication and Adherence to AHMs Among Prevalent and New 
Users
Racial/Ethnic Groups
Prevalence of Refill Adherence by 
Levels of Communication, % (95% CI)* OR (95% CI)†
Low High Unadjusted
Adjusted for Patient, Provider, and 
Healthcare System– Level Factors‡
Black patients
All users, n=2571 35 (32– 38) 42 (39– 45) 1.42 (1.18– 1.71) 1.38 (1.14– 1.67)
New users, n=783 29 (25– 34) 36 (31– 41) 1.47 (1.04– 2.07) 1.45 (1.01– 2.07)
Non– Hispanic White patients
All users, n=4771 50 (48– 52) 50 (48– 52) 0.98 (0.86– 1.12) 0.96 (0.86– 1.12)
New users, n=1434 41 (37– 45) 46 (42– 51) 1.24 (0.96– 1.58) 1.20 (0.93– 1.55)
Hispanic patients
All users, n=1675 41 (37– 44) 43 (38– 47) 1.09 (0.86– 1.39) 1.02 (0.80– 1.31)
New users, n=584 32 (26– 38) 33 (26– 40) 1.03 (0.67– 1.57) 0.91 (0.58– 1.43)
Other race/ethnicity§
All users, n=689 43 (37– 49) 43 (36– 51) 1.02 (0.70– 1.50) 1.10 (0.73– 1.65)
New users, n=257 38 (28– 47) 39 (26– 52) 1.04 (0.53– 2.04) 1.01 (0.47– 2.16)
*Prevalence, odds ratios (ORs), and 95% CIs are weighted by Medical Expenditure Panel Survey’s sampling weights.
†Referent group is “low.”
‡Patient- level factors: age; sex; geographic region of residence; education; speaks English at home; marital status; employment status; poverty status; ever 
delay, forego, or make change in prescription medicine because of cost; ever delay, forego, or make change in treatment because of cost; have blood checked 
in the past year; duration of hypertension; used antihypertension medications (AHMs) in the baseline year (adjusted for among only new users); adherent in year 
1 (adjusted for among only new users); poor physical health; poor mental health; cognitive limitations; coronary heart disease; angina; myocardial infarction; 
other heart diseases; stroke; diabetes mellitus; arthritis; asthma; chronic bronchitis; cancer. Provider- level factors: provider specialty; provider and patient are of 
the same sex; provider and patient are of the same race. Healthcare system– level factors: uninsured; usual source of payment; payment source; out- of- pocket 
payments; number of office visits.
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of the patient- clinician relationships (communication 
[P interaction <0.001] and SDM [P interaction <0.01]) 
and adherence to antihypertensive medications. In 
contrast to the associations observed among Black 
patients, none of the associations between patient- 
clinician constructs and adherence to antihypertensive 
medications were statistically significant among non– 
Hispanic White patients, Hispanic patients, and other 
(Native Americans, Alaskans, Asians, Hawaiians and 
Pacific Islanders) racial/ethnic groups (Tables 2 and 3).
DISCUSSION
We show Black adults with hypertension who self- 
report as having high levels of communication and 
a high degree of involvement with their clinicians in 
making decisions about treatment were more likely 
to take antihypertensive medications as prescribed 
compared with those with lower levels of communi-
cation and involvement in SDM. These associations 
were independent of all provider characteristics: the 
clinician’s race/ethnicity, sex, and specialty. Individual- 
and healthcare system– level factors did not influence 
these associations nor did the observed associations 
appear to have been influenced by potential reverse 
associations between patient- clinician relationships 
and adherence. In contrast, neither communication 
nor SDM were associated with adherence to antihy-
pertensive medications among non– Hispanic White 
patients, Hispanic patients, and other racial/ethnic 
groups. This suggests that the observed associations 
between patient- provider relationships and adherence 
are robust. Our analysis provides new data on the as-
sociation between SDM and adherence to antihyper-
tensive medications among Black adult patients with 
hypertension and also expands the growing evidence 
base on the potential benefits of patient- clinician com-
munication on adherence to antihypertensive medica-
tions among Black patients.28– 31 Most importantly, we 
have addressed methodological limitations that have 
been identified in previously published studies on this 
topic.
The observed positive associations between com-
munication and adherence corroborates data from 
studies conducted among Black patients28– 31 and 
among the general population.27 However, our find-
ings contradict those previously reported by Cooper 
et al (2011)63 among 279 underserved primary care 
patients with hypertension randomized to physicians 
who received communication skills training versus a 
control physician group. There are no published data 
on the associations between SDM and adherence 
Table 3. Associations Between SDM and Adherence to AHMs Among Prevalent and New Users
Racial/Ethnic Groups
Prevalence of Refill Adherence by 
Levels of SDM, % (95% CI)* OR (95% CI)†
Low High Unadjusted
Adjusted for Patient- , Provider- , and 
Healthcare System– Level Factors‡
Black patients
All users, n=2354 37 (34– 39) 40 (37– 43) 1.32 (1.09– 1.60) 1.32 (1.08– 1.61 )
New users, n=692 30 (26– 35) 25 (19– 30) 1.49 (1.03– 2.14) 1.59 (1.09– 2.32 )
White patients
All users, n=4495 50 (48– 52) 51 (48– 53) 1.02 (0.89– 1.17) 1.01 (0.88– 1.16)
New users, n=1344 42 (38– 46) 48 (43– 53) 1.25 (0.97– 1.61) 1.23 (0.95– 1.60)
Hispanic patients
All users, n=1494 42 (38– 46) 41 (37– 46) 0.97 (0.75– 1.25) 0.92 (0.71– 1.20)
New users, n=510 34 (28– 41) 33 (25– 40) 0.93 (0.59– 1.45) 0.84 (0.51– 1.37)
Other race/ethnicity§
All users, n=625 42 (36– 47) 47 (39– 55) 1.24 (0.82, 1.87) 1.29 (0.84– 1.99)
New users, n=232 37 (27– 46) 40 (26– 55) 1.16 (0.56– 2.39) 1.20 (0.51– 2.83)
SDM indicates shared decision- making.
*Prevalence, odds ratios (ORs), and 95% CIs are weighted by Medical Expenditure Panel Survey’s sampling weights.
†Referent group is “low.”
‡Patient- level factors: age; sex; geographic region of residence; education; speaks English at home; marital status; employment status; poverty status; ever 
delay, forego, or make change in prescription medicine because of cost; ever delay, forego, or make change in treatment because of cost; have blood checked 
in the past year; duration of hypertension; used antihypertensive medications (AHMs) in the baseline year (adjusted for among only new users); adherent in year 
1 (adjusted for among only new users); poor physical health; poor mental health; cognitive limitations; coronary heart disease; angina; myocardial infarction; 
other heart diseases; stroke; diabetes mellitus; arthritis; asthma; chronic bronchitis; cancer. Provider- level factors: provider specialty; provider and patient are of 
the same sex; provider and patient are of the same race. Healthcare system– level factors: uninsured; usual source of payment; payment source; out- of- pocket 
payments; number of office visits.
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to antihypertensive medications specifically among 
Black adults. Among a racially diverse population, 
overall medication adherence to either oral hypogly-
cemic, lipid- lowering, or antihypertensive medication 
increased with higher scores of SDM, although no as-
sociation was observed among only users of antihy-
pertensive medications.48 Schoenthaler et al (2018)64 
also reported that SDM was positively associated with 
adherence to antihypertensive medications among 
43 Black patients and 32 White patients with hyper-
tension. In a systematic review of intervention stud-
ies, SDM interventions did not improve adherence to 
medications among the general population.65
The effects of patient- clinician communication 
and SDM on medication adherence has largely been 
postulated via indirect pathways involving affective- 
cognitive outcomes including knowledge, attitudes, 
and satisfaction with care, which are all known de-
terminants of adherence to medications.26,58 It has 
also been theorized that effective communication 
increases patients’ knowledge about their medica-
tions and medical conditions. The complex regimens 
required for patients with more severe hypertension 
and/or comorbidities,66 both more common among 
Black individuals, may particularly require effective 
communication to enhance long- term adherence. 
Indeed, we observed that patients who reported that 
their clinician always, versus not, explained things in 
a way that was easy to understand were more likely 
to be adherent (OR, 1.40; 95% CI, 1.15– 1.72). Also, 
by listening attentively, respecting the sociocultural 
views of Black patients, and making them partners 
in decisions about their medications, clinicians may 
be better positioned to intervene by providing accu-
rate evidence- based information and or switching 
medication in the instance where patients are expe-
riencing drug adverse effects. Our data confirmed 
that patients who reported that their clinician always 
listened carefully, versus not, were more likely to be 
adherent (OR, 1.38; 95% CI, 1.13– 1.69).
The lack of association between patient- provider 
relationships and adherence among non– Hispanic 
White patients, Hispanic patients, and other racial/eth-
nic groups was unexpected. We suspect that Black 
patients with hypertension may have more complex 
drug regimens67 compared with other racial/ethnic 
groups because of the disproportionately higher se-
verity of hypertension (uncontrolled BP) and burden 
of chronic comorbidities.68,69 Therefore, it is plausible 
that higher levels of patient- provider communication 
and involvement in SDM probably had higher effects 
on mitigating the adverse effects of complex anti-
hypertensive regimens on adherence among Black 
patients but not among other racial/ethnic groups. 
Additional research is needed to test empirically the 
hypothesis that our observed racial/ethnic disparities 
in the associations between patient- provider commu-
nication and involvement in SDM are moderated by 
hypertension symptom severity and the complexity of 
the antihypertensive regimen. It is also possible that 
providers who communicate effectively and involve 
Black patients in SDM may be less likely to be biased 
against Black patients. Black patients are likely to be 
more trusting of such providers and, consequently, 
more likely to adhere to treatment recommendations. 
Future research on whether patient- provider relation-
ships can close racial/ethnic disparities in adherence 
to antihypertensive medications is warranted.
Strengths and Limitations
Several limitations of this study need to be considered 
when interpreting our findings. First, because this is an 
observational study we cannot rule out the effects of 
potential unmeasured confounding although we ad-
justed for several patient- , provider- , and healthcare 
system– level confounders. Second, while MRA is a 
validated measure of refill adherence, it was meas-
ured based on self- reported medication use and may 
therefore be liable to recall bias. Any such bias, how-
ever, would have had a differential effect on measured 
associations since we expect recall bias to be similar 
between the groups compared by levels of communi-
cation and SDM. MRA as a refill adherence measure 
does not account for switching between antihyperten-
sive medications after initiation. Third, we measured 
communication and SDM from the patient’s perspec-
tive without the clinician’s perspective. However, it has 
been shown that patient- perceived communication 
and SDM are more important in assessing patient out-
comes.26 Fourth, we could not ascertain from the data 
how long patients and clinicians interacted with each 
other. However, given that responses reflect the pa-
tient’s experience with a clinician in the past 12 months 
and that on average patients had 9 (SD, 19) office visits 
during the same period, it is highly likely that patients 
and clinicians had an established ongoing relationship. 
Fifth, because the MEPS data do not include unique 
provider identification numbers, we could not verify 
whether patients received antihypertensive therapy 
from the same provider for whom they had provided 
responses to regarding their communication and in-
volvement in the SDM process. However, given that 
the patients included in our analysis had frequent office 
visits and that 81% reported that their clinician asked 
about other medications that were prescribed by other 
doctors, we believe that our findings reflect patients’ 
experiences with clinicians in general, irrespective of 
whether the clinician was the prescriber of the antihy-
pertensive medications.
Notwithstanding these limitations, our study also fea-
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and research. First, our sensitivity analysis shows 
that the observed associations are robust against 
the effects of potential reverse associations between 
patient- clinician relationships and adherence. Second, 
by using a longitudinal cohort study design to leverage 
a national survey data set, we have contributed criti-
cal data on the associations between patient- clinician 
relationships and adherence to antihypertensive medi-
cations among Black adults in the United States. Third, 
our findings are directly translatable to clinical practice 
because we defined patient- clinician relationships from 
standard survey instruments that are currently in use 
by healthcare providers in the United States.
CONCLUSIONS
Patient- clinician communication and SDM were iden-
tified as modifiable predictors of adherence to antihy-
pertensive medications among Black patients but not 
among non– Hispanic White patients, Hispanic patients, 
or other racial/ethnic groups. Development of testable 
interventions to enhance these elements will support 
further assessment of the relationship between these 
patient- clinician factors and adherence to antihyperten-
sive medications among Black adults. Based on our 
findings, we recommend that clinicians and healthcare 
systems consider emphasizing communication and 
SDM processes within patient- centered models as a 
strategy to improve adherence to antihypertensive med-
ications among adult Black patients with hypertension.
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Table S1. Distributions of single items and overall communication and shared decision-
making scores before imputation. 
Question 
Response 
Yes No Never Sometimes Usually Always Missing 
Communication        
How often health providers 
listened carefully to you 










How often health providers 
explained things in a way that 
was easy to understand 










How often providers showed 
respect for what you had to say 










How often health providers 
spent enough time with you 










Shared decision-making†        
Does the USC provider usually 
ask the person to help make 
decisions between a choice of 
treatments 










Does the USC provider usually 
ask about and show respect for 
medical, traditional, and 
alternative treatments that the 
person is happy with 










Does the USC provider usually 
ask about prescription 
medications and treatments 





    73 
(2.7) 
†Shared decision-making is defined based on responses to all four communication items plus the three 
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Table S2. Distributions of single items and overall communication and shared decision-
making scores after imputation. 
Question Yes No Never Sometimes Usually Always 
Communication       
How often health providers listened 
carefully to you 








How often health providers explained 
things in a way that was easy to 
understand 








How often providers showed respect 
for what you had to say 








How often health providers spent 
enough time with you 








Shared decision-making†       
Does the USC provider usually ask 
the person to help make decisions 
between a choice of treatments 








Does the USC provider usually ask 
about and show respect for medical, 
traditional, and alternative treatments 
that the person is happy with 








Does the USC provider usually ask 
about prescription medications and 






    
†Shared decision-making is defined based on responses to all four communication items plus the three 
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Table S3. Distribution of baseline characteristics before imputation. 
 Communication 
Involvement in shared decision-
making (SDM) 





n = 1,135 
SDT§ 
Low, 
n = 881 
High, 
n = 935 
SDT§ 
Demographics       
Age, mean (SD), years      57 (13) 59(13) 0.14 57 (13) 55 (13) 0.07 
Age categories, years       
   18 – 44 196 (18) 156 (15) 0.08 153 (18) 135 (17) 0.04 
   45 – 64 564 (52) 578 (52) 0.01 453 (53) 473 (50) 0.05 
   ≥ 65 341 (29) 401 (33) 0.08 275 (29) 327 (33) 0.08 
Sex 
      
Female 701 (64) 744 (63) 0.02 574 (63) 614 (64) 0.02 
Male 400 (36) 391 (37) 0.02 307 (37) 321 (36) 0.02 
Geographic region of residence       
Midwest 192 (19) 201 (18) 0.01 151 (18) 158 (17) 0.04 
Northeast 139 (11) 160 (13) 0.07 124 (12) 129 (12) 0.00 
South 710 (64) 729 (65) 0.04 559 (63) 606 (66) 0.08 
West 60 (7) 45 (3) 0.17 47 (6) 42 (4) 0.10 
Education       
   Up to high school         684 (57) 688 (57) 0.00 551 (58) 560 (56) 0.03 
   College and beyond  417 (43) 447 (43) 0.00 330 (42) 375 (44) 0.03 
Speaking English at home       
   English     1094 (99) 1127 (99) 0.03 876 (99) 928 (99) 0.00 
   Non-English 7 (1) 8 (1) 0.03 5 (1) 7 (1) 0.00 
Socioeconomic       
Marital status       
   Married      708 (63) 709 (58) 0.11 573 (62) 571 (58) 0.07 
   Not married 393 (37) 426 (42) 0.11 308 (38) 364 (42) 0.07 
Employment status       
   Employed 404 (37) 444 (39) 0.01 311 (35) 364 (39) 0.02 
   Unemployed 697 (63) 691 (61) 0.01 570 (65) 571 (61) 0.02 
Poverty status       
   Above poverty level 775 (77) 816 (78) 0.02 616 (76) 677 (79) 0.06 
   Below poverty level        326 (23) 319 (22) 0.02 265 (24) 258 (21) 0.06 
Cost-related barriers       
Ever delay, forego or make change in 
prescription medicine because of cost 
81 (11) 36 (4) 0.26 55 (11) 37 (4) 0.25 
Ever delay, forego or make change in 
treatment because of cost  
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Hypertension-related       
Have blood checked in the past year 1069 (98) 1106 (98) 0.02 854 (98) 913 (98) 0.00 
Used AHM in the baseline year 777 (69) 793 (69) 0.00 634 (71) 661 (70) 0.02 
Duration of hypertension, mean (SD), 
years 
13 (11) 14 (11) 0.04 13 (11) 14 (12) 0.04 
Chronic comorbidities 
      
Poor physical health 205 (18) 140 (11) 0.21 158 (17) 129 (13) 0.10 
Poor mental health 88 (9) 53 (5) 0.15 65 (8) 54 (6) 0.06 
Have cognitive limitations 153 (13) 125 (10) 0.010 128 (13) 112 (10) 0.08 
CHD 109 (10) 130 (10) 0.01 99 (11) 116 (11) 0.01 
Angina 65 (6) 46 (4) 0.13 55 (6) 40 (4) 0.10 
Myocardial infarction 86 (7) 92 (8) 0.02 81 (9) 79 (7) 0.06 
Other heart diseases 214 (20) 187 (17) 0.08 172 (19) 173 (19) 0.01 
Stroke 139 (13) 133 (10) 0.08 115 (13) 123 (11) 0.05 
Diabetes 333 (29) 395 (33) 0.09 278 (29) 322 (33) 0.07 
Arthritis 602 (56) 576 (50) 0.14 490 (57) 496 (51) 0.12 
Asthma 172 (16) 182 (16) 0.01 139 (15) 163 (17) 0.04 
Chronic bronchitis 70 (5) 61 (5) 0.01 60 (6) 51 (5) 0.04 
Cancer 116 (10) 117 (9) 0.02 88 (10) 108 (10) 0.01 
Provider characteristics 
      
Clinician specialty 
      
General/Family practice/Internal 
Medicine 
300 (31) 362 (38) 0.15 267 (32) 313 (37) 0.12 
Other Medical doctor 28 (3) 21 (2) 0.08 17 (2) 24 (2) 0.01 
Specialist (Cardiologist/Nephrologist) 106 (12) 94 (10) 0.09 82 (10) 87 (11) 0.04 
Other provider 13 (1) 13 (1) 0.00 14 (2) 10 (1) 0.04 
Provider not human 566 (55) 577 (53) 0.04 501 (57) 501 (52) 0.01 
Same sex as patient 455 (45) 464 (47) 0.04 400 (47) 400 (45) 0.05 
Same race as patient 95 (10) 111 (12) 0.07 57.8 (10) 59.1 (12) 0.08 
Healthcare system factors 
      
Uninsured    104 (8) 71 (5) 0.13 76 (8) 56 (6) 0.08 
Have usual source of payment 962 (89) 1033 (94) 0.16 787 (90) 847 (93) 0.11 
Payment source is Medicaid 257 (20) 260 (20) 0.00 222 (21) 212 (20) 0.03 
Payment source is Medicare 262 (22) 276 (23) 0.01 223 (23) 235 (24) 0.01 
Payment source is private insurance 420 (43) 479 (49) 0.12 330 (43) 399 (50) 0.13 
Out-of-pocket payments, mean (SD), 
dollars 
324 (674) 325 (716) 0.00 350 (756) 312 (677) 0.05 
Counts of office visits, mean (SD) 11 (20) 9 (18) 0.08 11 (22) 10 (18) 0.06 
SD, standard deviation; STD, standardized difference test 
†Frequencies are absolute counts whereas %s are weighted by the MEPS survey weights 
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Table S4. Associations between ordinal-level communication and shared decision-
making scores and adherence to antihypertensive medications among Blacks. 
Patient-provider 
relationships 





Adjusted for Provider 
and Healthcare 
System-level factors≠ 
Adjusted for Patient, 
Provider and Healthcare 
System-level factors 
Communicationa     
All users, n = 2,571 1.12 (1.06, 1.19) 1.12 (1.05, 1.19) 1.14 (1.07, 1.21) 1.14 (1.07, 1.22) 
New users, n = 783 1.19 (1.07, 1.33) 1.19 (1.05, 1.35) 1.20 (1.07, 1.35) 1.21 (1.06, 1.39) 
Shared decision-
making†  
    
All users, n = 2,354 1.09 (1.04, 1.15) 1.10 (1.05, 1.16) 1.09 (1.04, 1.14) 1.08 (1.04, 1.15) 
New users, n = 692 1.12 (1.03, 1.23) 1.15 (1.04, 1.27) 1.12 (1.02, 1.23) 1.14 (1.04, 1.26) 
 
†Modeled as ordinal scale variables: Communication (0 – 4); shared decision-making (0 – 7) 
 
§Patient-level factors: Age; Sex; Geographic region of residence; Education; Speake English at home; 
Marital status, Employment status, Poverty status, Ever delay, forego or make change in prescription 
medicine because of cost; Ever delay, forego or make change in treatment because of cost; Have blood 
checked in the past year; Duration of hypertension; Used AHM in the baseline year (adjusted for among 
only new users);  Adherent in year 1 (adjusted for among only new users); Poor physical health; Poor 
mental health; Have cognitive limitations; Coronary heart disease; Angina; Myocardial infarction; Other 
heart diseases; Stroke; Diabetes; Arthritis; Asthma; Chronic bronchitis; Cancer. 
≠Provider-level factors: Provider specialty; Provider and patient are of the same sex; Provider and 
patient are of the same race; Healthcare system factors: Uninsured; Have usual source of payment; 
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Table S5. Association between adherence and individual items of communication and 






Prevalence of Refill 
Adherence, 
% (95% CI) 
 

























      
All users,  
n = 2,571 









 n = 783 










How often health 
providers 
explained things 
in a way that was 
easy to 
understand 
      
All users,  
n = 2,571 











 n = 783 













for what you had 
to say 
      
All users,  
n = 2,571 











 n = 783 








How often health 
providers spent 
enough time with 
you 
      
All users,  
n = 2,571 











 n = 783 










Does the USC 
provider usually 
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All users,  
n = 2,665 








New users,  
n = 795 










 Does the USC 
provider usually 
ask about and 





the person is 
happy with 
      
All users,  
n = 2,665 










New users,  
n = 795 










       




















    
All users,  
n = 2,665 










New users,  
n = 795 










CI, confidence interval 
 
†Referent group is “Never/Sometimes/Usually” 
§Referent group is “No” 
 
*Patient-level factors: Age; Sex; Geographic region of residence; Education; Speake English at home; 
Marital status, Employment status, Poverty status, Ever delay, forego or make change in prescription 
medicine because of cost; Ever delay, forego or make change in treatment because of cost; Have blood 
checked in the past year; Duration of hypertension; Used AHM in the baseline year (adjusted for among 
only new users);  Adherent in year 1 (adjusted for among only new users); Poor physical health; Poor 
mental health; Have cognitive limitations; Coronary heart disease; Angina; Myocardial infarction; Other 
heart diseases; Stroke; Diabetes; Arthritis; Asthma; Chronic bronchitis; Cancer. 
≠Provider-level factors: Provider specialty; Provider and patient are of the same sex; Provider and 
patient are of the same race; Healthcare system factors: Uninsured; Have usual source of payment; 
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